Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 1.63
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Undervalued vs peers
Data is available to registered users only
Data is available to registered users only
About
MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for...
Company Valuation
Considering past and projected metrics, the stock is 'cheaper' than its peers. Specifically, the stock is undervalued on EV/EBITDA.
Data is available to registered users only
Buy
Sell